Virginia Beach, Virginia-based Predictive Technology Group, Inc., (PRED) has been issued a patent by the United States Patent and Trademark Office covering a progesterone/progestin/cannabis therapeutic and Method of Use for the treatment of endometriosis. PRED subsidiary Predictive Therapeutics, LLC, (PRx) now has exclusive rights to the patent (US Patent 9,149,499).
According to the patent application abstract (US 9149499 B1), the product is a compound comprised of a cannabis portion and at least one portion of progestin and a portion of progesterone. It may optionally also include a non-steroidal anti-inflammatory drug (NSAID) component. The compound may be administered in either pill or pellet form (for oral use or for subdermal implantation, respectively), as an injectable solution, or as a suppository, and is intended to treat subjects having or at increased risk of developing — especially genetically determined risk — the common gynecological disorder endometriosis. The compound may also be used for treating other disorders such as chronic pain, and more specifically chronic pelvic pain, or as a contraceptive.